Skip to content

Home

info@nutrigenomicsinstitute.com (+34) 91 9619057
My Account
Linkedin page opens in new windowFacebook page opens in new windowInstagram page opens in new window

Instituto Nutrigenomica

Nutrigenomics Institute
Nutrigenomics and Nutrigenetics Online Courses
Nutrigenomics Institute
  • About Us
  • Our Courses
    • ONLINE COURSE ON NUTRIGENOMICS FOR PROFESSIONALS OF NUTRITION
    • ONLINE COURSE ON NUTRIGENOMICS FOR HEALTH AND SPORTS
    • ONLINE ADVANCED COURSE ON NUTRIGENETICS AND NUTRIGENOMICS FOR PROFESSIONALS OF NUTRITION
  • Teachers
    • Dr. José Serrano
    • Dr. Ana B. Granado-Serrano
    • Dr. Èlia Obis
  • Tests
  • Testimonials
  • FAQS
  • News
  • Contact
  • Account
    • My Courses
    • Login|Logout
My Account
  • About Us
  • Our Courses
    • ONLINE COURSE ON NUTRIGENOMICS FOR PROFESSIONALS OF NUTRITION
    • ONLINE COURSE ON NUTRIGENOMICS FOR HEALTH AND SPORTS
    • ONLINE ADVANCED COURSE ON NUTRIGENETICS AND NUTRIGENOMICS FOR PROFESSIONALS OF NUTRITION
  • Teachers
    • Dr. José Serrano
    • Dr. Ana B. Granado-Serrano
    • Dr. Èlia Obis
  • Tests
  • Testimonials
  • FAQS
  • News
  • Contact
  • Account
    • My Courses
    • Login|Logout

Genetic Associations Between Modifiable Risk Factors and Alzheimer Disease

Jun262023

Genetic Associations Between Modifiable Risk Factors and Alzheimer Disease

 

Question  What are the genetic associations between modifiable risk factors and Alzheimer disease (AD)?

Findings  In this genetic association study using a mendelian randomization framework with the largest genomic data sets to date, including 39 106 participants with clinically diagnosed AD and 401 577 control participants without AD, genetically determined increased high-density lipoprotein cholesterol and increased systolic blood pressure were associated with higher risk of AD.

Meaning  These findings suggest that genetically determined increased high-density lipoprotein cholesterol and systolic blood pressure may be involved in AD pathogenesis, which may thus inspire new drug targeting and improved early dementia prevention.

Abstract

Importance  An estimated 40% of dementia is potentially preventable by modifying 12 risk factors throughout the life course. However, robust evidence for most of these risk factors is lacking. Effective interventions should target risk factors in the causal pathway to dementia.

Objective  To comprehensively disentangle potentially causal aspects of modifiable risk factors for Alzheimer disease (AD) to inspire new drug targeting and improved prevention.

Design, Setting, and Participants  This genetic association study was conducted using 2-sample univariable and multivariable mendelian randomization. Independent genetic variants associated with modifiable risk factors were selected as instrumental variables from genomic consortia. Outcome data for AD were obtained from the European Alzheimer & Dementia Biobank (EADB), generated on August 31, 2021. Main analyses were conducted using the EADB clinically diagnosed end point data. All analyses were performed between April 12 and October 27, 2022.

Exposures  Genetically determined modifiable risk factors.

Main Outcomes and Measures  Odds ratios (ORs) and 95% CIs for AD were calculated per 1-unit change of genetically determined risk factors.

Results  The EADB-diagnosed cohort included 39 106 participants with clinically diagnosed AD and 401 577 control participants without AD. The mean age ranged from 72 to 83 years for participants with AD and 51 to 80 years for control participants. Among participants with AD, 54% to 75% were female, and among control participants, 48% to 60% were female. Genetically determined high-density lipoprotein (HDL) cholesterol concentrations were associated with increased odds of AD (OR per 1-SD increase, 1.10 [95% CI, 1.05-1.16]). Genetically determined high systolic blood pressure was associated with increased risk of AD after adjusting for diastolic blood pressure (OR per 10–mm Hg increase, 1.22 [95% CI, 1.02-1.46]). In a second analysis to minimize bias due to sample overlap, the entire UK Biobank was excluded from the EADB consortium; odds for AD were similar for HDL cholesterol (OR per 1-SD unit increase, 1.08 [95% CI, 1.02-1.15]) and systolic blood pressure after adjusting for diastolic blood pressure (OR per 10–mm Hg increase, 1.23 [95% CI, 1.01-1.50]).

Conclusions and Relevance  This genetic association study found novel genetic associations between high HDL cholesterol concentrations and high systolic blood pressure with higher risk of AD. These findings may inspire new drug targeting and improved prevention implementation.

 

Article Information

JAMA Netw Open. 2023;6(5):e2313734. doi:10.1001/jamanetworkopen.2023.13734

 

Date: May 17, 2023

Link: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2805006

European Alzheimer’s & Dementia Biobank Mendelian Randomization (EADB-MR) Collaboration

Corresponding Author: Ruth Frikke-Schmidt, MD, DMSc, PhD, Department of Clinical Biochemistry, Copenhagen University Hospital–Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark (ruth.frikke-schmidt@regionh.dk).

Author Contributions: Drs Luo and Frikke-Schmidt had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Luo, Thomassen, Dichgans, Rujescu, Hausner, Düzel, Tegos, Boada, Nacmias, Daniele, Tsolaki, Ingelsson, Frikke-Schmidt.

Acquisition, analysis, or interpretation of data: Luo, Thomassen, Bellenguez, Grenier-Boley, de Rojas, Castillo Morales, Parveen, Küçükali, A. Nicolas, Peters, Schneider, Dichgans, Scherbaum, Deckert, Riedel-Heller, Hausner, Molina-Porcel, Düzel, Grimmer, Wiltfang, Heilmann-Heimbach, Moebus, Scarmeas, Clarimon, Moreno, Perez-Tur, Bullido, Pastor, Sánchez-Valle, Alvarez, Boada, García-González, Puerta Fuentes, Mir, Real, Piñol-Ripoll, García-Alberca, Royo, Rodríguez-Rodriguez, Soininen, Kuulasmaa, de Mendonça, Mehrabian, Hort, Vyhnalek, van der Lee, Graff, Papenberg, Giedraitis, Boland, Bacq-Daian, Deleuze, G. Nicolas, Dufouil, Pasquier, Hanon, Debette, Grünblatt, Popp, Benussi, Galimberti, Arosio, Mecocci, Solfrizzi, Parnetti, Squassina, Tremolizzo, Borroni, Sorbi, Caffarra, Seripa, Rainero, Masullo, Spalletta, Williams, Amouyel, Jessen, Kehoe, Rossi, Sánchez-Juan, Sleegers, Andreassen, Hiltunen, van Duijn, Sims, van der Flier, Ruiz, Ramirez, Lambert, Frikke-Schmidt.

Drafting of the manuscript: Luo, Dichgans, Boada, Kuulasmaa, Tsolaki, Hiltunen, Frikke-Schmidt.

Critical revision of the manuscript for important intellectual content: Luo, Thomassen, Bellenguez, Grenier-Boley, de Rojas, Castillo Morales, Parveen, Küçükali, A. Nicolas, Peters, Schneider, Dichgans, Rujescu, Scherbaum, Deckert, Riedel-Heller, Hausner, Molina-Porcel, Düzel, Grimmer, Wiltfang, Heilmann-Heimbach, Moebus, Tegos, Scarmeas, Clarimon, Moreno, Perez-Tur, Bullido, Pastor, Sánchez-Valle, Alvarez, Boada, García-González, Puerta Fuentes, Mir, Real, Piñol-Ripoll, García-Alberca, Royo, Rodríguez-Rodriguez, Soininen, de Mendonça, Mehrabian, Hort, Vyhnalek, van der Lee, Graff, Papenberg, Giedraitis, Boland, Bacq-Daian, Deleuze, G. Nicolas, Dufouil, Pasquier, Hanon, Debette, Grünblatt, Popp, Benussi, Galimberti, Arosio, Mecocci, Solfrizzi, Parnetti, Squassina, Tremolizzo, Borroni, Nacmias, Sorbi, Caffarra, Seripa, Rainero, Daniele, Masullo, Spalletta, Williams, Amouyel, Jessen, Kehoe, Rossi, Sánchez-Juan, Sleegers, Ingelsson, Andreassen, van Duijn, Sims, van der Flier, Ruiz, Ramirez, Lambert, Frikke-Schmidt.

 

Statistical analysis: Luo, Thomassen, Bellenguez, Castillo Morales, Parveen, Tegos, Real, Kuulasmaa, van der Lee, Amouyel, van Duijn.

Obtained funding: Deckert, Riedel-Heller, Düzel, Scarmeas, Clarimon, Graff, G. Nicolas, Dufouil, Debette, Popp, Benussi, Sorbi, Spalletta, Williams, Jessen, Sánchez-Juan, Sleegers, Andreassen, van Duijn, Sims, Ruiz, Ramirez, Lambert, Frikke-Schmidt.

Administrative, technical, or material support: Bellenguez, Grenier-Boley, Schneider, Molina-Porcel, Grimmer, Heilmann-Heimbach, Moreno, Pastor, Royo, Soininen, Vyhnalek, Graff, Papenberg, Giedraitis, Boland, Deleuze, G. Nicolas, Popp, Galimberti, Mecocci, Tremolizzo, Seripa, Daniele, Williams, Amouyel, Tsolaki, Ingelsson, Andreassen, Sims, Ruiz, Lambert, Frikke-Schmidt.

Supervision: Thomassen, Riedel-Heller, Düzel, Wiltfang, Scarmeas, Mir, Piñol-Ripoll, García-Alberca, Rodríguez-Rodriguez, Mehrabian, Boland, Arosio, Mecocci, Solfrizzi, Parnetti, Nacmias, Caffarra, Rainero, Masullo, Jessen, Sleegers, Hiltunen, van Duijn, Ruiz, Lambert, Frikke-Schmidt.

Nutrigenomics Institute is not responsible for the comments and opinions included in this article

 

Category: NewsJune 26, 2023Leave a comment
Tags: Alzheimer nutritionAlzheimer researchcholesterol Alzheimer riskgenetics Alzheimerhypertension Alzheimer riskLDL Alzheimer

RELATED POSTS

A committee of experts proposes rethinking the concept of obesity and BMI
January 20, 2025
Scientists discover a “mortality timer” in our cells
January 13, 2025
Gut microbiota: a new path to treat obesity
January 8, 2025
What are dietary exosomes and which foods include them?
December 16, 2024

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Post comment

  • A committee of experts proposes rethinking the concept of obesity and BMI
    January 20, 2025
  • Scientists discover a “mortality timer” in our cells
    January 13, 2025
  • Gut microbiota: a new path to treat obesity
    January 8, 2025
  • What are dietary exosomes and which foods include them?
    December 16, 2024
  • The yo-yo effect: Adipose tissue retains an epigenetic memory of obesity after weight loss
    December 9, 2024